NICE reviewing use of Avastin for wet AMD

Article

The UK's National Health Service (NHS) is reported to be looking at the use of Avastin in lieu of Lucentis.

The UK's National Health Service (NHS) is reported to be looking at the use of Avastin for patients at risk from blindness, which is an unlicensed treatment in place of the more expensive, but licensed product, Lucentis.

The National Institute for Health and Clinical Excellence (NICE) is reviewing the situation, having made the decision to back Lucentis two years ago. BBC News reported that Richard Smith, vice president of the Royal College of Opthalmologists, described it as: “Simply good house-keeping” given the circumstances.

NICE said it was not expecting to make a decision until next year.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.